Hostname: page-component-7b7567c8c-jswmv Total loading time: 0 Render date: 2026-11-15T10:22:57.448Z Has data issue: false hasContentIssue false
  • English
  • Français

Anti-NMDA receptor encephalitis: clinical and research implications

Published online by Cambridge University Press:  30 May 2013

Rajkumar A.P.
Rajkumar A.P.*
Affiliation:
Department of Biomedicine, Aarhus University, Aarhus, DenmarkCentre for Psychiatric research, Aarhus University hospital, Risskov, DenmarkDepartment of Psychiatry, Christian Medical College, Vellore, India
*
E-mail: apr@hum-gen.au.dk
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Information

Type
Editorial
Information
Acta Neuropsychiatrica , Volume 25 , Issue 3 , June 2013, pp. 125 - 127
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 2013 

Anti-NMDA receptor encephalitis is a severe neuropsychiatric disease, caused by autoimmune antibodies against N-methyl-d-aspartate glutamate receptors (NMDAR). Although clinical descriptions suggest that anti-NMDAR encephalitis has existed for centuries, this disease was formally recognised following the publication of a case series in 2007 (Reference Dalmau, Tuzun and Wu1). Clinical presentation of anti-NMDAR encephalitis may vary widely, but it often includes the following four phases, prodromal phase, psychotic and/or seizure phase, unresponsive phase and hyperkinetic phase (Reference Peery, Day and Dunn2). These clinical phases may manifest with a plethora of psychiatric presentations encompassing delirium, psychosis, catatonia, affective syndromes and anxiety. Patients with anti-NMDAR encephalitis may initially arrive at the emergency psychiatric services or at the psychiatric intensive care units with only psychiatric symptoms and may pose major diagnostic challenges to the treating psychiatrists (Reference Van de Riet and Schieveld3).

Anti-NMDAR encephalitis is not rare (Reference Peery, Day and Dunn2). Prevalence of anti-NMDAR antibodies among the first episode patients, who met the DSM-IV diagnostic criteria for schizophrenia, has been reported as 6.5% (Reference Zandi, Irani and Lang4). Anti-NMDAR encephalitis is more prevalent among young women with tumours, especially ovarian teratomas. Para neoplastic autoimmunity and infection-induced molecular mimicry may explain the production of auto-antibodies against NMDAR (Reference Peery, Day and Dunn2). Around 41% of patients with anti-NMDAR encephalitis do not have any detectable tumours (Reference Dalmau, Lancaster and Martinez-Hernandez5). The diagnosis of anti-NMDAR encephalitis is usually clinched by detecting the antibodies in the patient's serum or cerebrospinal fluid (CSF). Patients with anti-NMDAR encephalitis respond poorly to standard psychopharmacological agents, but 75% of patients recover well with specific interventions such as immunosuppression and tumour resection (Reference Peery, Day and Dunn2). Unless the disease is diagnosed early and treated appropriately, the risk for mortality or severe disability will be as high as 25% (Reference Dalmau, Gleichman and Hughes6). Such high mortality risk and availability of specific treatments emphasise the importance of recognising anti-NMDAR encephalitis during busy clinical practice of psychiatry (Reference Barry, Hardiman and Healy7).

In this issue, Maat et al. (Reference Maat, De Graaff and Van Beveren8) presents the first Dutch cohort of 15 patients with anti-NMDAR encephalitis. Eighty per cent of their patients presented prominent psychiatric symptoms. Two-thirds of them were initially managed by psychiatric services and there were two fatalities. Their retrospective data corroborate prior evidence that early diagnosis of anti-NMDAR encephalitis leads to favourable clinical outcomes. They confirm that the patients with anti-NMDAR encephalitis do not respond well to antipsychotic medications and benzodiazepines, but they improve considerably with immunosuppression. Their findings provide the impetus to briefly highlight the following issues, which are relevant to many clinical and academic psychiatrists.

Clinical implications

As early diagnosis and prompt management of anti-NMDAR encephalitis can save many lives and can prevent severe disability, the clinical psychiatrists need to consider the following:

  1. 1. Screening all patients with first episode psychosis for anti-NMDAR encephalitis is desirable (Reference Lennox, Coles and Vincent9) but not feasible in all clinical settings. Cost-effectiveness of such screening strategy has not been evaluated so far. Hence, there is a clinical need to identify the patients at high risk by their clinical presentations. Abrupt onset, rapid progression, female gender, seizures, abnormal movements, disorientation, stupor, incontinence, fluctuations in psychopathology, autonomic dysfunction and absence of past or family history of psychiatric morbidity or substance use may indicate the investigations for anti-NMDAR encephalitis. Clinical teams should formulate local policies and explicit guidelines to facilitate early diagnosis of anti-NMDAR encephalitis.

  2. 2. Patients, who have first episode psychosis and atypical clinical presentations, often undergo neuroimaging. However, magnetic resonance imaging of the brain can be absolutely normal in 50% of patients with anti-NMDAR encephalitis (Reference Peery, Day and Dunn2). Electroencephalography is more sensitive, but less specific to diagnose anti-NMDAR encephalitis. Immunoassays to detect auto-antibodies should be first performed in the patients’ sera. A seronegative result but high clinical suspicion of anti-NMDAR encephalitis will indicate lumbar puncture. CSF immunoassays are more sensitive than the serum assays to diagnose anti-NMDAR encephalitis (Reference Peery, Day and Dunn2). Once the diagnosis is made, a comprehensive evaluation for tumours is mandatory.

  3. 3. Neuropsychiatric diseases with predominant psychiatric presentations can create conflicts among the treating teams and ward managers. Clinical psychiatrists should establish multidisciplinary collaborative care including neurologists, intensivists and surgeons at the earliest to facilitate the recovery of patients with anti-NMDAR encephalitis.

  4. 4. Anti-NMDAR encephalitis may lead to long-term cognitive deficits (Reference Chapman and Vause10). After the recovery from acute phase, clinical psychiatrists need to plan for neuropsychological assessment and cognitive rehabilitation. Despite prompt treatment, 25% of patients with anti-NMDAR encephalitis may continue to suffer moderate to severe neuropsychiatric difficulties (Reference Peery, Day and Dunn2). As anti-NMDAR encephalitis severely disrupts one's personal, social and professional life, there is a clinical need for holistic care, psychosocial support and occupational therapy.

  5. 5. Relapses can occur in 25% of patients, especially those who do not have any removable tumour. Hence, recovered patients will require comprehensive education and long-term follow-up. A diagnosis of anti-NMDAR encephalitis does not rule out the possibility of primary psychiatric disorders later in life. Comprehensive clinical assessment, including detailed mental status examination, should consider all relevant differential diagnoses during each clinical presentation.

Research directives

Anti-NMDAR encephalitis sets the stage for investigating the NMDA glutamate receptor hypothesis for schizophrenia (Reference Schwartz, Sachdeva and Stahl11) and opens the following research avenues:

  1. 1. Clinical presentations indicating the diagnosis of anti-NMDAR encephalitis have been recognised from clinical experience and from published case series so far. There is a need for studies with appropriate control groups to identify the clinical predictors, which can distinguish those, who are likely to have anti-NMDAR encephalitis, among all patients with first episode psychosis.

  2. 2. Schizophrenia is a group of heterogeneous disorders and its aetiology is multifactorial. Between the two sets of schizophrenia and anti-NMDAR encephalitis, there can be a common subset of patients with schizophrenia with NMDAR auto-antibodies, contributing to their psychopathology (Reference Van de Riet and Schieveld3). We need better epidemiological studies to establish the prevalence of NMDAR auto-antibodies and the risk conferred by such antibodies in schizophrenia.

  3. 3. Evidence base for specific interventions to treat anti-NMDAR encephalitis is not strong. The risks and benefits of chronic immunosuppression remain uncertain (Reference Peery, Day and Dunn2). We need prospective intervention trials to develop standard treatment algorithms to manage anti-NMDAR encephalitis.

  4. 4. Health economic studies, evaluating the cost-effectiveness of screening all patients with first episode psychosis for anti-NMDAR encephalitis and for other antibody-mediated encephalitis, are desired.

  5. 5. Immunopathogenesis of anti-NMDAR encephalitis has not been fully understood yet (Reference Peery, Day and Dunn2). Genetic studies, rodent models using immunisation strategies and further molecular studies may enhance our understanding of this intriguing neuropsychiatric disease.

Disclosure

The author does not have any competing interests to declare.

References

1.Dalmau, J, Tuzun, E, Wu, HYet al. Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25–36.CrossRefGoogle ScholarPubMed
2.Peery, HE, Day, GS, Dunn, Set al. Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmun Rev 2012;11:863–872.CrossRefGoogle ScholarPubMed
3.Van de Riet, EH, Schieveld, JN. First-onset psychosis, anti-NMDAR encephalitis, schizophrenia and Consultation-Liaison psychiatry. Gen Hosp Psychiatry 2013; doi: 10.1016/j.genhosppsych.2013.1001.1014. Epub ahead of print.CrossRefGoogle ScholarPubMed
4.Zandi, MS, Irani, SR, Lang, Bet al. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 2011;258:686–688.CrossRefGoogle ScholarPubMed
5.Dalmau, J, Lancaster, E, Martinez-Hernandez, Eet al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63–74.CrossRefGoogle ScholarPubMed
6.Dalmau, J, Gleichman, AJ, Hughes, EGet al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091–1098.CrossRefGoogle ScholarPubMed
7.Barry, H, Hardiman, O, Healy, DGet al. Anti-NMDA receptor encephalitis: an important differential diagnosis in psychosis. Br J Psychiatry 2011;199:508–509.CrossRefGoogle ScholarPubMed
8.Maat, P, De Graaff, E, Van Beveren, NMet al. Psychiatric phenomena as initial manifestation of encephalitis by anti-NMDAR antibodies. Acta Neuropsychiatr 2013; doi: 10.1111/acn.12013.CrossRefGoogle ScholarPubMed
9.Lennox, BR, Coles, AJ, Vincent, A. Antibody-mediated encephalitis: a treatable cause of schizophrenia. Br J Psychiatry 2012;200:92–94.CrossRefGoogle ScholarPubMed
10.Chapman, MR, Vause, HE. Anti-NMDA receptor encephalitis: diagnosis, psychiatric presentation, and treatment. Am J Psychiatry 2011;168:245–251.CrossRefGoogle ScholarPubMed
11.Schwartz, TL, Sachdeva, S, Stahl, SM. Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia. Curr Pharm Des 2012;18:1580–1592.CrossRefGoogle ScholarPubMed